By Prasad S. Adusumilli, MD, FACS, FCCP Posted: November 12, 2019 My colleagues and I conducted a phase I clinical trial of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy in […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events